Compare PSEC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | NNNN |
|---|---|---|
| Founded | 2004 | 2021 |
| Country | United States | Germany |
| Employees | 8 | 27 |
| Industry | Finance/Investors Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | PSEC | NNNN |
|---|---|---|
| Price | $2.50 | $26.65 |
| Analyst Decision | Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 4.6M | 12.8K |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | ★ 20.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $7.03 |
| 52 Week High | $3.77 | $55.65 |
| Indicator | PSEC | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 47.85 |
| Support Level | N/A | $26.31 |
| Resistance Level | $2.86 | $30.21 |
| Average True Range (ATR) | 0.08 | 2.10 |
| MACD | -0.02 | -0.30 |
| Stochastic Oscillator | 10.26 | 15.58 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).